The company said net sales for Q2 2025 were $2.077 billion on a reported basis, up 7.0%, up 5.4% on a constant currency basis and up 2.8% on an organic constant currency basis. Net earnings were $152.8 million, or $411.2 million on an adjusted basis.

1. 01

   The company said net sales for Q2 2025 were $2.077 billion on a reported basis, up 7.0%, up 5.4% on a constant currency basis and up 2.8% on an organic constant currency basis. Net earnings were $152.8 million, or $411.2 million on an adjusted basis.

2. 02

   Zimmer Biomet reported diluted earnings per share of $0.77 for Q2 2025, compared with $1.18 a year earlier, and adjusted diluted earnings per share of $2.07, up 3.0%. The company also said acquisition, integration, divestiture and related expenses for the same quarter were $78.9 million.

3. 03

   The company said it is narrowing its full-year 2025 reported revenue change outlook to 6.7% to 7.7% from 5.7% to 8.2%, and raising its adjusted diluted EPS outlook to $8.10 to $8.30 from $7.90 to $8.10.

4. 04

   The company said net cash provided by operating activities was $761.0 million for the 6 months ended June 30, 2025, and business combination investments, net of acquired cash, were $1,226.3 million over the same period. The company said it acquired Paragon 28 in April 2025.

Analysis scope · Filing body and confirmed press-release exhibitWe analyzed the opening part of the filing body and confirmed exhibits, within a length limit. This is not a review of other exhibits, investor presentations or the full earnings call.

AI summarized the filing and translated the summary into English; it may differ from the original. For reference only, not investment advice. AI translated the published Korean report into English. Figures are copied as filed, not recalculated.

Original filing

The filing as submitted to SEC EDGAR. You can check the figures and statements of this summary against it.